Entropy Technologies LP Acquires 1,747 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Entropy Technologies LP lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 173.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,753 shares of the biopharmaceutical company’s stock after buying an additional 1,747 shares during the quarter. Entropy Technologies LP’s holdings in Regeneron Pharmaceuticals were worth $2,127,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of REGN. Renaissance Technologies LLC lifted its stake in shares of Regeneron Pharmaceuticals by 635.5% during the 1st quarter. Renaissance Technologies LLC now owns 66,802 shares of the biopharmaceutical company’s stock worth $51,614,000 after acquiring an additional 57,720 shares during the last quarter. Gabelli Funds LLC grew its position in Regeneron Pharmaceuticals by 19.5% in the 1st quarter. Gabelli Funds LLC now owns 2,197 shares of the biopharmaceutical company’s stock valued at $1,697,000 after acquiring an additional 358 shares during the last quarter. GC Wealth Management RIA LLC grew its position in Regeneron Pharmaceuticals by 510.9% in the 1st quarter. GC Wealth Management RIA LLC now owns 2,297 shares of the biopharmaceutical company’s stock valued at $1,775,000 after acquiring an additional 1,921 shares during the last quarter. Public Employees Retirement System of Ohio increased its stake in Regeneron Pharmaceuticals by 6.6% in the first quarter. Public Employees Retirement System of Ohio now owns 43,886 shares of the biopharmaceutical company’s stock worth $33,908,000 after purchasing an additional 2,710 shares during the period. Finally, Compound Planning Inc. increased its stake in Regeneron Pharmaceuticals by 8.1% in the first quarter. Compound Planning Inc. now owns 1,811 shares of the biopharmaceutical company’s stock worth $1,400,000 after purchasing an additional 135 shares during the period. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on REGN. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Royal Bank Of Canada decreased their price objective on shares of Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Finally, HSBC lowered their price objective on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $787.88.

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $656.01 on Monday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $635.78 and a two-hundred day simple moving average of $714.09. The firm has a market cap of $69.35 billion, a PE ratio of 15.98, a price-to-earnings-growth ratio of 1.45 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. During the same period in the prior year, the business earned $8.22 EPS. The business’s revenue for the quarter was up 19.0% compared to the same quarter last year. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts remain constructive ahead of Regeneron’s upcoming quarterly results, with one note saying the company is positioned to beat earnings expectations. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: Guggenheim raised its price target on Regeneron, signaling continued Wall Street confidence in the stock’s longer-term upside. Guggenheim Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00
• Neutral Sentiment: Multiple law firms are advertising deadlines and investor-rights notices related to the already-filed Regeneron securities class action, keeping the issue in the spotlight but not adding new allegations. The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN
• Neutral Sentiment: Additional firms, including Faruqi & Faruqi, Schall, and others, issued similar class-action reminders, which extends the legal-news flow around REGN. Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
• Negative Sentiment: Several lawsuits claim Regeneron misled investors about clinical-trial protocol and statistical risks, with one report citing a sharp selloff and an estimated $11 billion market-cap hit after the trial failure disclosure. Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure – HBSS

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.